Results Patients From 2013 through March 2014 July, a complete of 300 patients at 19 centers in five countries underwent randomization according to the amended protocol. The evaluation populations are demonstrated in Figure 2. The baseline features were equivalent in the three study groups . Efficacy Venograms that could be evaluated were obtained in 281 of the 293 patients who also received study medication . Seven of the patients whose venograms could be evaluated underwent venography outside the 8-to-12-day postoperative period, and only 1 1 had deep-vein thrombosis. These 7 patients had been excluded from the per-protocol population. There have been no other major process violations.Food and Drug Administration today posted a public health communication about metal-on-metal hip elements found in total hip arthroplasty . The American Academy of Orthopaedic Surgeons appreciates this comprehensive and well-considered consider the concerns surrounding the usage of these implants. The FDA’s communication also keeps each one of the essential stakeholders in mind: patients, potential individuals, orthopaedic surgeons and various other doctors. With the patient’s basic safety, health, and quality of life always in mind, the users of the AAOS will continue to work with device manufacturers and agencies such as the FDA to talk about knowledge and communicate any potential concerns.